Lonza Group traded at 517.20 this Friday February 6th, decreasing 1.00 or 0.19 percent since the previous trading session. Looking back, over the last four weeks, Lonza lost 5.90 percent. Over the last 12 months, its price fell by 14.34 percent. Looking ahead, we forecast Lonza Group to be priced at 512.24 by the end of this quarter and at 475.80 in one year, according to Trading Economics global macro models projections and analysts expectations.
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.